BIOMIRA REPORTS LUNG CANCER DRUG STUDY RESULTS

Biomira has reported results from a clinical trial of its non-small cell lung cancer drug, Stimuvax.

The final survival results from an analysis of the Phase IIb data confirmed a median survival in patients with Stage IIIB cancer of 30.6 months with Stimuvax, while patients in the same stage who were in a control test group had a median survival of 13.3 months.